0R1B

Biogen (0R1B)

Biogen Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:LSE:0R1B

일자	시간	출처	헤드라인	심볼	기업
2025/01/31	20:30	UK Regulatory	Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union	LSE:0R1B	Biogen Inc
2025/01/27	08:33	UK Regulatory	FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease	LSE:0R1B	Biogen Inc
2025/01/23	21:30	UK Regulatory	FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA	LSE:0R1B	Biogen Inc
2025/01/14	09:05	UK Regulatory	FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease	LSE:0R1B	Biogen Inc
2024/11/19	15:00	UK Regulatory	Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity	LSE:0R1B	Biogen Inc
2024/11/15	01:23	UK Regulatory	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease	LSE:0R1B	Biogen Inc
2024/10/31	08:30	UK Regulatory	Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference	LSE:0R1B	Biogen Inc
2024/10/30	07:00	UK Regulatory	Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases	LSE:0R1B	Biogen Inc
2024/10/29	21:00	UK Regulatory	Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer	LSE:0R1B	Biogen Inc
2024/10/28	21:30	UK Regulatory	Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025	LSE:0R1B	Biogen Inc
2024/10/27	09:15	UK Regulatory	Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024	LSE:0R1B	Biogen Inc
2024/10/24	20:30	UK Regulatory	Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference	LSE:0R1B	Biogen Inc
2024/10/22	20:30	UK Regulatory	Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024	LSE:0R1B	Biogen Inc
2024/10/09	20:30	UK Regulatory	Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients	LSE:0R1B	Biogen Inc
2024/10/08	20:30	UK Regulatory	New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA	LSE:0R1B	Biogen Inc
2024/09/24	14:00	UK Regulatory	UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024	LSE:0R1B	Biogen Inc
2024/09/12	20:30	UK Regulatory	Biogen Board Appoints Two New Independent Directors	LSE:0R1B	Biogen Inc
2024/09/04	20:30	UK Regulatory	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA	LSE:0R1B	Biogen Inc
2024/07/31	06:15	UK Regulatory	New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC	LSE:0R1B	Biogen Inc
2024/07/30	20:30	UK Regulatory	Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease	LSE:0R1B	Biogen Inc
2024/07/26	20:20	UK Regulatory	Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union	LSE:0R1B	Biogen Inc
2024/03/06	21:30	UK Regulatory	New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy	LSE:0R1B	Biogen Inc
2024/03/05	06:15	UK Regulatory	Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting	LSE:0R1B	Biogen Inc
2024/02/23	21:00	UK Regulatory	Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP	LSE:0R1B	Biogen Inc
2024/02/13	06:06	UK Regulatory	Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia	LSE:0R1B	Biogen Inc
2024/01/31	21:30	UK Regulatory	Biogen to Realign Resources for Alzheimer's Disease Franchise	LSE:0R1B	Biogen Inc
2023/08/07	01:07	Alliance News	CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed	LSE:0R1B	Biogen Inc
2023/08/06	22:17	Alliance News	Biogens, Sage Therapeutics postpartum depression treatment approved	LSE:0R1B	Biogen Inc
2023/06/09	20:12	Alliance News	*Nasdaq halts trading of Biogen stock	LSE:0R1B	Biogen Inc
2020/01/13	23:28	Alliance News	Pfizer Could Net USD635 Million As Biogen Acquires Alzheimer's Drug	LSE:0R1B	Biogen Inc